Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel Punts On PET For Initial Diagnosis Of Cancer In Dense-Breasted Women

This article was originally published in The Gray Sheet

Executive Summary

Public input prior to the formulation of questions for a technology assessment potentially could have allowed a more thorough evaluation of PET scanning in the initial diagnosis of cancer in dense-breasted women by the Medicare Coverage Advisory Committee's Diagnostic Imaging Panel June 19

You may also be interested in...



PET Cancer Coverage Decision Saves Dense-Breast Indication For Another Day

The Centers for Medicare & Medicaid Services is inviting interested parties to submit a separate coverage request for FDG-PET in women who have dense breast tissue

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel